Search

Your search keyword '"Valenciano M"' showing total 134 results
Start Over Author "Valenciano M"
134 results on '"Valenciano M"'

1. Systematic review of seroprevalence of SARS-CoV-2 antibodies and appraisal of evidence, prior to the widespread introduction of vaccine programmes in the WHO European Region, January–December 2020

Author

Vaughan, Aisling, primary, Duffell, Erika, additional, Freidl, Gudrun S, additional, Lemos, Diogo Simão, additional, Nardone, Anthony, additional, Valenciano, M, additional, Subissi, Lorenzo, additional, Bergeri, Isabel, additional, K Broberg, Eeva, additional, Penttinen, Pasi, additional, Pebody, Richard, additional, and Keramarou, Maria, additional

Published
2023
Full Text
View/download PDF

2. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: a systematic review and meta-analysis of standardized population-based studies

Author

Bergeri, I, Whelan, MG, Ware, H, Subissi, L, Nardone, A, Lewis, HC, Li, Z, Ma, X, Valenciano, M, Cheng, B, Al Ariqi, L, Rashidian, A, Okeibunor, J, Azim, T, Wijesinghe, P, Le, L-V, Vaughan, A, Pebody, R, Vicari, A, Yan, T, Yanes-Lane, M, Cao, C, Clifton, DA, Cheng, MP, Papenburg, J, Buckeridge, D, Bobrovitz, N, Arora, RK, Van Kerkhove, MD, and Group, Unity Studies Collaborator

Subjects
Adult, SARS-CoV-2, Low and middle income countries, Virus testing, COVID-19, Respiratory infections, General Medicine, Metaanalysis, Medical risk factors, Cross-Sectional Studies, Seroepidemiologic Studies, Humans, Vaccination and immunization, SARS CoV 2, Child, Pandemics, COVID 19
Abstract

Background Our understanding of the global scale of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data underestimate infection and cannot infer on population immunity; there is a predominance of asymptomatic infections, and uneven access to diagnostics. We meta-analyzed SARS-CoV-2 seroprevalence studies, standardized to those described in the World Health Organization’s Unity protocol (WHO Unity) for general population seroepidemiological studies, to estimate the extent of population infection and seropositivity to the virus 2 years into the pandemic. Methods and findings We conducted a systematic review and meta-analysis, searching MEDLINE, Embase, Web of Science, preprints, and grey literature for SARS-CoV-2 seroprevalence published between January 1, 2020 and May 20, 2022. The review protocol is registered with PROSPERO (CRD42020183634). We included general population cross-sectional and cohort studies meeting an assay quality threshold (90% sensitivity, 97% specificity; exceptions for humanitarian settings). We excluded studies with an unclear or closed population sample frame. Eligible studies—those aligned with the WHO Unity protocol—were extracted and critically appraised in duplicate, with risk of bias evaluated using a modified Joanna Briggs Institute checklist. We meta-analyzed seroprevalence by country and month, pooling to estimate regional and global seroprevalence over time; compared seroprevalence from infection to confirmed cases to estimate underascertainment; meta-analyzed differences in seroprevalence between demographic subgroups such as age and sex; and identified national factors associated with seroprevalence using meta-regression. We identified 513 full texts reporting 965 distinct seroprevalence studies (41% low- and middle-income countries [LMICs]) sampling 5,346,069 participants between January 2020 and April 2022, including 459 low/moderate risk of bias studies with national/subnational scope in further analysis. By September 2021, global SARS-CoV-2 seroprevalence from infection or vaccination was 59.2%, 95% CI [56.1% to 62.2%]. Overall seroprevalence rose steeply in 2021 due to infection in some regions (e.g., 26.6% [24.6 to 28.8] to 86.7% [84.6% to 88.5%] in Africa in December 2021) and vaccination and infection in others (e.g., 9.6% [8.3% to 11.0%] in June 2020 to 95.9% [92.6% to 97.8%] in December 2021, in European high-income countries [HICs]). After the emergence of Omicron in March 2022, infection-induced seroprevalence rose to 47.9% [41.0% to 54.9%] in Europe HIC and 33.7% [31.6% to 36.0%] in Americas HIC. In 2021 Quarter Three (July to September), median seroprevalence to cumulative incidence ratios ranged from around 2:1 in the Americas and Europe HICs to over 100:1 in Africa (LMICs). Children 0 to 9 years and adults 60+ were at lower risk of seropositivity than adults 20 to 29 (p < 0.001 and p = 0.005, respectively). In a multivariable model using prevaccination data, stringent public health and social measures were associated with lower seroprevalence (p = 0.02). The main limitations of our methodology include that some estimates were driven by certain countries or populations being overrepresented. Conclusions In this study, we observed that global seroprevalence has risen considerably over time and with regional variation; however, over one-third of the global population are seronegative to the SARS-CoV-2 virus. Our estimates of infections based on seroprevalence far exceed reported Coronavirus Disease 2019 (COVID-19) cases. Quality and standardized seroprevalence studies are essential to inform COVID-19 response, particularly in resource-limited regions.

Published
2023

3. AB0123 ENTEROCOCCUS GALLINARUM IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.

Author

Vega Sevilla, L. F., primary, Alvarez-González, O. E., additional, Riega-Torres, J. C., additional, Rubio Torres, D. C., additional, Skinner Taylor, C. M., additional, Vera Cabrera, L., additional, Cardenas-de la Garza, J. A., additional, Aguilera Valenciano, M. A., additional, Escalante, W., additional, Guerra, H., additional, and Galarza-Delgado, D. Á., additional

Published
2023
Full Text
View/download PDF

4. Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

Author

Epi Infectieziekten Team 1, Child Health, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Lazar, Mihaela, Demlová, Regina, Wirtz, Gil, Amerali, Marina, Dürrwald, Ralf, Pál Kunstár, Mihály, Kissling, Esther, Bacci, Sabrina, Valenciano, M, I-MOVE-COVID-19 hospital study team, Epi Infectieziekten Team 1, Child Health, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Lazar, Mihaela, Demlová, Regina, Wirtz, Gil, Amerali, Marina, Dürrwald, Ralf, Pál Kunstár, Mihály, Kissling, Esther, Bacci, Sabrina, Valenciano, M, and I-MOVE-COVID-19 hospital study team

Published
2023

5. Transmission of SARS-CoV-2 in standardised first few X cases and household transmission investigations: A systematic review and meta-analysis

Author

Lewis, HC, Marcato, AJ, Meagher, N, Valenciano, M, Villanueva-Cabezas, J-P, Spirkoska, V, Fielding, JE, Karahalios, A, Subissi, L, Nardone, A, Cheng, B, Rajatonirina, S, Okeibunor, J, Aly, EA, Barakat, A, Jorgensen, P, Azim, T, Wijesinghe, PR, Le, L-V, Rodriguez, A, Vicari, A, Van Kerkhove, MD, McVernon, J, Pebody, R, Price, DJ, Bergeri, I, Lewis, HC, Marcato, AJ, Meagher, N, Valenciano, M, Villanueva-Cabezas, J-P, Spirkoska, V, Fielding, JE, Karahalios, A, Subissi, L, Nardone, A, Cheng, B, Rajatonirina, S, Okeibunor, J, Aly, EA, Barakat, A, Jorgensen, P, Azim, T, Wijesinghe, PR, Le, L-V, Rodriguez, A, Vicari, A, Van Kerkhove, MD, McVernon, J, Pebody, R, Price, DJ, and Bergeri, I

Abstract

We aimed to estimate the household secondary infection attack rate (hSAR) of SARS-CoV-2 in investigations aligned with the WHO Unity Studies Household Transmission Investigations (HHTI) protocol. We conducted a systematic review and meta-analysis according to PRISMA 2020 guidelines. We searched Medline, Embase, Web of Science, Scopus and medRxiv/bioRxiv for "Unity-aligned" First Few X cases (FFX) and HHTIs published 1 December 2019 to 26 July 2021. Standardised early results were shared by WHO Unity Studies collaborators (to 1 October 2021). We used a bespoke tool to assess investigation methodological quality. Values for hSAR and 95% confidence intervals (CIs) were extracted or calculated from crude data. Heterogeneity was assessed by visually inspecting overlap of CIs on forest plots and quantified in meta-analyses. Of 9988 records retrieved, 80 articles (64 from databases; 16 provided by Unity Studies collaborators) were retained in the systematic review; 62 were included in the primary meta-analysis. hSAR point estimates ranged from 2% to 90% (95% prediction interval: 3%-71%; I 2 = 99.7%); I 2 values remained >99% in subgroup analyses, indicating high, unexplained heterogeneity and leading to a decision not to report pooled hSAR estimates. FFX and HHTI remain critical epidemiological tools for early and ongoing characterisation of novel infectious pathogens. The large, unexplained variance in hSAR estimates emphasises the need to further support standardisation in planning, conduct and analysis, and for clear and comprehensive reporting of FFX and HHTIs in time and place, to guide evidence-based pandemic preparedness and response efforts for SARS-CoV-2, influenza and future novel respiratory viruses.

Published
2022

7. Seroprevalence of SARS-CoV-2 antibodies prior to the widespread introduction of vaccine programmes in the WHO European Region, January - December 2020: a systematic review

Author

Vaughan, A, primary, Duffell, EF, additional, Friedl, GS, additional, Lemos, DS, additional, Funk, T, additional, Nardone, A, additional, Valenciano, M, additional, Subissi, L, additional, Bergeri, I, additional, Broberg, E, additional, Penttinen, P, additional, Pebody, R, additional, and Keramarou, M, additional

Published
2021
Full Text
View/download PDF

8. Exploring the nasopharyngeal microbiota composition in infants with whooping cough: A test-negative case-control study

Author

Rocafort M, Henares-Bonilla D, Brotons-de los Reyes P, Barrabeig I, Launes-Montana C, Merdrignac L, Valenciano M, Domínguez A, Godoy P, and Munoz-Almagro C

Abstract

PURPOSE: The purpose of this study was to characterize the nasopharyngeal microbiota of infants with possible and confirmed pertussis compared to healthy controls. METHODS: This prospective study included all infants

Published
2021

9. Incidence and severity of pertussis hospitalisations in infants aged less than 1 year in 37 hospitals of six EU/EEA countries, results of PERTINENT sentinel pilot surveillance system, December 2015 to December 2018

Author

Merdrignac L, Aït El Belghiti F, Pandolfi E, Jané M, Murphy J, Fabiánová K, García Cenoz M, Flem E, Guillot S, Tozzi AE, Carmona G, Habington A, Zavadilová J, Navasués A, Bøås H, Lévy-Brühl D, Ferretti B, Miguel Lanaspa Pérez, O'Sullivan N, Krížová P, Fernandino L, Bekkevold T, Hanslik T, Munoz-Almagro C, Bacci S, Spiteri G, Valenciano M, Moren A, PERTINENT Group, and PERTINENT group

Subjects
pertussis, active surveillance, hospital surveillance, pertussis incidence
Abstract

IntroductionPERTINENT is a pilot active surveillance system of infants hospitalised with pertussis in six European Union/European Economic Area countries (37 hospitals, seven sites).AimThis observational study aimed to estimate annual pertussis incidence per site from 2016 to 2018 and respective trends between 2017 and 2018. Pertussis cases were described, including their severity.MethodsWe developed a generic protocol and laboratory guidelines to harmonise practices across sites. Cases were hospitalised infants testing positive for Bordetella pertussis by PCR or culture. Sites collected demographic, clinical, laboratory data, vaccination status, and risk/protective factors. We estimated sites' annual incidences by dividing case numbers by the catchment populations.ResultsFrom December 2015 to December 2018, we identified 469 cases (247 males; 53%). The median age, birthweight and gestational age were 2.5 months (range: 0-11.6; interquartile range (IQR): 2.5), 3,280 g (range: 700-4,925; IQR: 720) and 39 weeks (range: 25-42; IQR: 2), respectively. Thirty cases (6%) had atypical presentation either with cough or cyanosis only or with absence of pertussis-like symptoms. Of 330 cases with information, 83 (25%) were admitted to intensive care units including five deceased infants too young to be vaccinated. Incidence rate ratios between 2018 and 2017 were 1.43 in Czech Republic (p = 0.468), 0.25 in Catalonia (p = 0.002), 0.71 in France (p = 0.034), 0.14 in Ireland (p = 0.002), 0.63 in Italy (p = 0.053), 0.21 in Navarra (p = 0.148) and zero in Norway.ConclusionsIncidence appeared to decrease between 2017 and 2018 in all but one site. Enhanced surveillance of hospitalised pertussis in Europe is essential to monitor pertussis epidemiology and disease burden.

Published
2021

10. Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

Author

Rondy, M, Kissling, E, Emborg, Hd, Gherasim, A, Pebody, R, Trebbien, R, Pozo, F, Larrauri, A, Mcmenamin, J, Valenciano, M, Kaic, B, Kurecic Filipovic, S, Visekruna-Vucina, V, Pem Novosel, I, Lovric, Z, Petrović, G, Krause, Tg, Fischer, Tk, Lina, B, Falchi, Antonella, Vilcu, Am, Souty, C, Blanchon, T, van der Werf, S, Enouf, V, Behillil, S, Valette, M, Bernard-Stoecklin, S, Lévy-Bruhl, D, Launay, O, Loulergue, P, Lenzi, N, Lesieur, Z, L'Honneur, As, Galtier, F, Agostini, C, Serrand, C, Merle, C, Foulongne, V, Vanhems, P, Lainé, F, Lagathu, G, Carrat, F, Buda, S, Preuss, U, Prahm, K, Schweiger, B, Wedde, M, Heider, A, Martin, M, Biere, B, Duerrwald, R, Domegan, L, Coughlan, L, O’Donnell, J, Joyce, M, Collins, C, Dunford, L, Martin Moran, Josè Manuel, Tuite, G, Duffy, M, Connell, J, de Gascun, C, Rizzo, C, Bella, A, Alfonsi, V, Castrucci, Mr, Puzelli, S, Pagani, E, Ghisetti, V, Pariani, E, Baldanti, F, Palù, G, D'Agaro, P, Ansaldi, F, Affanni, P, Rossolini, Gm, Camilloni, B, Bagnarelli, P, Sanguinetti, M, Atripaldi, L, Chironna, M, Serra, C, Vitale, F, Germinario, C, Orsi, A, Manini, I, Montomoli, E, Napoli, C, Orsi, Gb, Casado, I, Castilla, J, Fernandino, L, Martínez-Baz, I, Ezpeleta, G, Navascués, A, Pérez-García, A, Aguinaga, A, Ezpeleta, C, Meijer, A, van den Brink, S, van der Hoek, W, Goderski, G, Wijsman, L, Bagheri, M, Dijkstra, F, de Lange, M, Marzec, T, Overduin, P, Teirlinck, A, Wentink, E, Donker, G, Marbus, S, van Gageldonk- Lafeber, R, Schneeberger, P, van Oosterheert JJ, Schweitzer, V, Groeneveld, G, Nunes, B, RIBEIRO MACHADO, CARLOS AUGUSTO, Rodrigues, Ap, DIAZ GOMEZ, MARIA VANESSA, Kislaya, I, Guiomar, R, Pechirra, P, Cristóvão, P, Costa, I, Panarra, A, Côrte-Real, R, Poças, J, João Peres, M, García Comas, L, Marisquerena, Mei, Galán, Jc, Folgueira, D, Gonzalez Carril, F, Sancho Martínez, R, Cilla, G, García Cenoz, M, Quiñones Rubio, C, Martinez Ochoa, E, Blasco, M, Gimenez Duran, J, Vanrell, Jm, Reina, J, Castrillejo, D, Gherasim, Am, Delgado, C, Oliva, J, Casas, I, García, M, Latorre, M, Milagro Beamonte AM, Martinez Sapiñ, A, Oribe Amores, M, Aizpurúa, A, Montes, Marco, Zakikhany, K, Brytting, M, Wiman, Å, Carnahan, A, Warburton, F, Djennad, A, Ellis, J, Andrews, N, Marques, D, Cottrell, S, Reynolds, Alexander, Gunson, R, Galiano, M, Lackenby, A, Robertson, C, O’Doherty, M, Sinnathamby, M, Yonova, I, Moore, C, Sartaj, M, de Lusignan, S, Zambon, M, Moren, A, Penttinen, P., Unión Europea, EpiConcept [Paris], Statens Serum Institut [Copenhagen], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Rondy M., Kissling E., Emborg H.-D., Gherasim A., Pebody R., Trebbien R., Pozo F., Larrauri A., McMenamin J., Valenciano M., Kaic B., Filipovic S.K., Visekruna-Vucina V., Novosel I.P., Lovric Z., Petrovic G., Krause T.G., Fische T.K., Lina B., Falchi A., Vilcu A.-M., Souty C., Blanchon T., van der Werf S., Enouf V., Behillil S., Valette M., Bernard-Stoecklin S., Levy-Bruhl D., Launay O., Loulergue P., Lenzi N., Lesieur Z., L'Honneur A.-S., Galtier F., Agostini C., Serrand C., Merle C., Foulongne V., Vanhems P., Laine F., Lagathu G., Carrat F., Buda S., Preuss U., Prahm K., Schweiger B., Wedde M., Heider A., Martin M., Biere B., Duerrwald R., Domegan L., Coughlan L., O'Donnell J., Joyce M., Collins C., Dunford L., Moran J., Tuite G., Duffy M., Connell J., de Gascun C., Rizzo C., Bella A., Alfonsi V., Castrucci M.R., Puzelli S., Pagani E., Ghisetti V., Pariani E., Baldanti F., Palu G., D'Agaro P., Ansaldi F., Affanni P., Rossolini G.M., Camilloni B., Bagnarelli P., Sanguinetti M., Atripaldi L., Chironna M., Serra C., Vitale F., Germinario C., Orsi A., Manini I., Montomoli E., Napoli C., Orsi G.B., Casado I., Castilla J., Fernandino L., Martinez-Baz I., Ezpeleta G., Navascues A., Perez-Garcia A., Aguinaga A., Ezpeleta C., Meijer A., van den Brink S., van der Hoek W., Goderski G., Wijsman L., Bagheri M., Dijkstra F., de Lange M., Marzec T., Overduin P., Teirlinck A., Wentink E., Donker G., Marbus S., van Gageldonk-Lafeber R., Schneeberger P., van Oosterheert J.J., Schweitzer V., Groeneveld G., Nunes B., Machado A., Rodrigues A.P., Gomez V., Kislaya I., Guiomar R., Pechirra P., Cristovao P., Costa I., Panarra A., Corte-Real R., Pocas J., Peres M.J., Comas L.G., Marisquerena M.E.I., Galan J.C., Folgueira M.D., Carril F.G., Martinez R.S., Cilla G., Cenoz M.G., Rubio C.Q., Ochoa E.M., Blasco M., Duran J.G., Vanrell J.M., Reina J., Castrillejo D., Gherasim A.M., Delgado C., Oliva J., Casas I., Garcia M., Latorre M., Beamonte A.M.M., Sapina A.M., Amores M.O., Aizpurua A., Montes M., Zakikhany K., Brytting M., Wiman A., Carnahan A., Warburton F., Djennad A., Ellis J., Andrews N., Marques D., Cottrell S., Reynolds A., Gunson R., Galiano M., Lackenby A., Robertson C., O'Doherty M., Sinnathamby M., Yonova I., Moore C., Sartaj M., de Lusignan S., Zambon M., Moren A., Penttinen P., Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Marc, Rondy, Esther, Kissling, Hanne-Dorthe, Emborg, Alin, Gherasim, Richard, Pebody, Ramona, Trebbien, Francisco, Pozo, Amparo, Larrauri, Jim, Mcmenamin, Marta, Valenciano, D'Agaro, Pierlanfranco, De Lusignan, S, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)

Subjects
0301 basic medicine, Male, Pediatrics, Epidemiology, viruses, Influenza B viru, influenza, influenza vaccine effectiveness, influenza vaccination, case control study, multicentre study, Europe, Europe, case control study, influenza, influenza vaccination, influenza vaccine effectiveness, multicentre study, 0302 clinical medicine, Influenza A Virus, H1N1 Subtype, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Interim, Pandemic, Influenza A Virus, 030212 general & internal medicine, QA, Influenza vaccine effectiveness, Child, media_common, Vaccine Effectiveness, Vaccination, virus diseases, Middle Aged, 3. Good health, Treatment Outcome, Influenza Vaccines, Child, Preschool, H3N2 Subtype, Female, Seasons, Influenza Vaccine, Rapid Communication, Human, Adult, RM, medicine.medical_specialty, Adolescent, Influenza vaccine, 030106 microbiology, Case control study, Multicentre study, European studies, Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA, 03 medical and health sciences, Virology, Influenza, Human, medicine, media_common.cataloged_instance, Humans, H1N1 Subtype, Vacina Antigripal, European Union, European union, Preschool, Pandemics, Aged, Influenza A Virus, H3N2 Subtype, Cuidados de Saúde, Public Health, Environmental and Occupational Health, Infant, Newborn, Infant, Influenza a, influenza vaccine effectivene, Newborn, Influenza, respiratory tract diseases, Influenza vaccination, Influenza B virus, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Determinantes da Saúde e da Doença, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology
Abstract

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates. Funding: The five studies have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446 to conduct the study in individuals aged 65 years or more. ECDC has contributed to fund some study sites of the EU-PC study under the Framework contract No ECDC/2014/026 for the individuals aged less than 65 years. All study teams are very grateful to all patients, general practitioners, paediatricians, hospital teams, laboratory teams, regional epidemiologists who have contributed to the studies. We acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiFlu Database used for this study. All submitters of data may be contacted directly via the GISAID website www.gisaid.org Sí

Published
2018

11. Exploring the Effect of Previous Inactivated Influenza Vaccination on Seasonal Influenza Vaccine Effectiveness against Medically Attended Influenza: Results of the European I-MOVE Multicentre Test-Negative Case-Control Study, 2011/2012-2016/2017

Author

Valenciano, M, Kissling, E, Larrauri, A, Nunes, B, Pitigoi, D, O'Donnell, J, Reuss, A, Horváth, Jk, Paradowska-Stankiewicz, I, Rizzo, C, Falchi, A, Daviaud, I, Brytting, M, Meijer, A, Kaic, B, Gherasim, A, Machado, A, Ivanciuc, A, Domegan, L, Schweiger, B, Ferenczi, A, Korczyńska, M, Bella, A, Vilcu, Am, Mosnier, A, Zakikhany, K, de Lange, M, Kurečić Filipovićović, S, Johansen, K, Moren, A, I-MOVE primary care multicentre case-control, Team., EpiConcept [Paris], Institute of Health Carlos III, Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Health Protection Surveillance Centre (HPSC), Department for Infectious Disease Epidemiology [Berlin], Robert Koch Institute [Berlin] (RKI), National Centre for Epidemiology [Budapest], National Institute of Public Health - National Institute of Hygiene [Poland], Istituto Superiore di Sanita [Rome], Università di Corsica Pasquale Paoli [Université de Corse Pascal Paoli], Partenaires INRAE, Réseau des Groupes Régionaux d'Observation de la Grippe (GROG), Coordination nationale, Public Health Agency of Sweden, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Croatian Institute of Public Health [Zagreb] (CIPH), Instituto Superiore di Sanità (ISS), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), European Centre for Disease Prevention and Control (ECDC), and Gestionnaire, HAL Sorbonne Université 5

Subjects
Infecções Respiratórias, Male, 0301 basic medicine, Epidemiology, [SDV]Life Sciences [q-bio], Efetividade da Vacina Antigripal, Influenza vaccinations, Seasonal influenza, 0302 clinical medicine, Previous Vaccination, Medicine, 030212 general & internal medicine, Child, Prospective cohort study, Vaccine effectiveness, Aged, 80 and over, education.field_of_study, Influenza vaccine, IMOVE, virus diseases, Case-control study, Middle Aged, multicentre study, 3. Good health, Vaccination, [SDV] Life Sciences [q-bio], Treatment Outcome, Infectious Diseases, Influenza Vaccines, Original Article, Female, influenza, Adult, Pulmonary and Respiratory Medicine, Adolescent, case-control study, 030106 microbiology, Population, Multicentre study, Young Adult, 03 medical and health sciences, Influenza, Human, Humans, Vacina Antigripal, education, Aged, vaccine effectiveness, case‐control study, business.industry, Cuidados de Saúde, Public Health, Environmental and Occupational Health, Original Articles, Estados de Saúde e de Doença, Influenza, Negative case, Determinantes da Saúde e da Doença, influenza vaccine, business, Demography
Abstract

Free PMC Article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086844/ I‐MOVE primary care multicentre case‐control team - Portugal: Baltazar Nunes, Ausenda Machado, Ana Paula Rodrigues, Verónica Gomez (Departamento de Epidemiologia, Instituto Nacional de Saúde Dr. Ricardo Jorge); Raquel Guiomar, Pedro Pechirra, Paula Cristóvão, Patrícia Conde, Inês Costa (Departamento de Doenças Infeciosas, Instituto Nacional de Saúde Dr. Ricardo Jorge) BACKGROUND: Results of previous influenza vaccination effects on current season influenza vaccine effectiveness (VE) are inconsistent. OBJECTIVES: To explore previous influenza vaccination effects on current season VE among population targeted for vaccination. METHODS: We used 2011/2012 to 2016/2017 I-MOVE primary care multicentre test-negative data. For each season, we compared current season adjusted VE (aVE) between individuals vaccinated and unvaccinated in previous season. Using unvaccinated in both seasons as a reference, we then compared aVE between vaccinated in both seasons, current only, and previous only. RESULTS: We included 941, 2645 and 959 influenza-like illness patients positive for influenza A(H1N1)pdm09, A(H3N2) and B, respectively, and 5532 controls. In 2011/2012, 2014/2015 and 2016/2017, A(H3N2) aVE point estimates among those vaccinated in previous season were -68%, -21% and -19%, respectively; among unvaccinated in previous season, these were 33%, 48% and 46%, respectively (aVE not computable for influenza A(H1N1)pdm09 and B). Compared to current season vaccination only, VE for both seasons' vaccination was (i) similar in two of four seasons for A(H3N2) (absolute difference [ad] 6% and 8%); (ii) lower in three of four seasons for influenza A(H1N1)pdm09 (ad 18%, 26% and 29%), in two seasons for influenza A(H3N2) (ad 27% and 39%) and in two of three seasons for influenza B (ad 26% and 37%); (iii) higher in one season for influenza A(H1N1)pdm09 (ad 20%) and influenza B (ad 24%). CONCLUSIONS: We did not identify any pattern of previous influenza vaccination effect. Prospective cohort studies documenting influenza infections, vaccinations and vaccine types are needed to understand previous influenza vaccinations' effects. European Centre for Disease Prevention and Control. Grant Number: ECDC/2014/026 European Union's Horizon 2020 research and innovation programme. Grant Number: 634446 WHO‐EURO info:eu-repo/semantics/publishedVersion

Published
2018

12. Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studies

Author

Rondy, M., Kissling, E., Emborg, H. -D., Gherasim, A., Pebody, R., Trebbien, R., Pozo, F., Larrauri, A., Mcmenamin, J., Valenciano, M., Kaic, B., Filipovic, S. K., Visekruna-Vucina, V., Novosel, I. P., Lovric, Z., Petrovic, G., Krause, T. G., Fische, T. K., Lina, B., Falchi, A., Vilcu, A. -M., Souty, C., Blanchon, T., van der Werf, S., Enouf, V., Behillil, S., Valette, M., Bernard-Stoecklin, S., Levy-Bruhl, D., Launay, O., Loulergue, P., Lenzi, N., Lesieur, Z., L'Honneur, A. -S., Galtier, F., Agostini, C., Serrand, C., Merle, C., Foulongne, V., Vanhems, P., Laine, F., Lagathu, G., Carrat, F., Buda, S., Preuss, U., Prahm, K., Schweiger, B., Wedde, M., Heider, A., Martin, M., Biere, B., Duerrwald, R., Domegan, L., Coughlan, L., O'Donnell, J., Joyce, M., Collins, C., Dunford, L., Moran, J., Tuite, G., Duffy, M., Connell, J., de Gascun, C., Rizzo, C., Bella, A., Alfonsi, V., Castrucci, M. R., Puzelli, S., Pagani, E., Ghisetti, V., Pariani, E., Baldanti, F., Palu, G., D'Agaro, P., Ansaldi, F., Affanni, P., Rossolini, G. M., Camilloni, B., Bagnarelli, P., Sanguinetti, Maurizio, Atripaldi, L., Chironna, M., Serra, C., Vitale, F., Germinario, C., Orsi, A., Manini, I., Montomoli, E., Napoli, C., Orsi, G. B., Casado, I., Castilla, J., Fernandino, L., Martinez-Baz, I., Ezpeleta, G., Navascues, A., Perez-Garcia, A., Aguinaga, A., Ezpeleta, C., Meijer, A., van den Brink, S., van der Hoek, W., Goderski, G., Wijsman, L., Bagheri, M., Dijkstra, F., de Lange, M., Marzec, T., Overduin, P., Teirlinck, A., Wentink, E., Donker, G., Marbus, S., van Gageldonk-Lafeber, R., Schneeberger, P., van Oosterheert, J. J., Schweitzer, V., Groeneveld, G., Nunes, B., Machado, A., Rodrigues, A. P., Gomez, V., Kislaya, I., Guiomar, R., Pechirra, P., Cristovao, P., Costa, I., Panarra, A., Corte-Real, R., Pocas, J., Peres, M. J., Comas, L. G., Marisquerena, M. E. I., Galan, J. C., Folgueira, M. D., Carril, F. G., Martinez, R. S., Cilla, G., Cenoz, M. G., Rubio, C. Q., Ochoa, E. M., Blasco, M., Duran, J. G., Vanrell, J. M., Reina, J., Castrillejo, D., Gherasim, A. M., Delgado, C., Oliva, J., Casas, I., Garcia, M., Latorre, M., Beamonte, A. M. M., Sapina, A. M., Amores, M. O., Aizpurua, A., Montes, M., Zakikhany, K., Brytting, M., Wiman, A., Carnahan, A., Warburton, F., Djennad, A., Ellis, J., Andrews, N., Marques, D., Cottrell, S., Reynolds, A., Gunson, R., Galiano, M., Lackenby, A., Robertson, C., O'Doherty, M., Sinnathamby, M., Yonova, I., Moore, C., Sartaj, M., de Lusignan, S., Zambon, M., Moren, A., Penttinen, P., Sanguinetti M. (ORCID:0000-0002-9780-7059), Rondy, M., Kissling, E., Emborg, H. -D., Gherasim, A., Pebody, R., Trebbien, R., Pozo, F., Larrauri, A., Mcmenamin, J., Valenciano, M., Kaic, B., Filipovic, S. K., Visekruna-Vucina, V., Novosel, I. P., Lovric, Z., Petrovic, G., Krause, T. G., Fische, T. K., Lina, B., Falchi, A., Vilcu, A. -M., Souty, C., Blanchon, T., van der Werf, S., Enouf, V., Behillil, S., Valette, M., Bernard-Stoecklin, S., Levy-Bruhl, D., Launay, O., Loulergue, P., Lenzi, N., Lesieur, Z., L'Honneur, A. -S., Galtier, F., Agostini, C., Serrand, C., Merle, C., Foulongne, V., Vanhems, P., Laine, F., Lagathu, G., Carrat, F., Buda, S., Preuss, U., Prahm, K., Schweiger, B., Wedde, M., Heider, A., Martin, M., Biere, B., Duerrwald, R., Domegan, L., Coughlan, L., O'Donnell, J., Joyce, M., Collins, C., Dunford, L., Moran, J., Tuite, G., Duffy, M., Connell, J., de Gascun, C., Rizzo, C., Bella, A., Alfonsi, V., Castrucci, M. R., Puzelli, S., Pagani, E., Ghisetti, V., Pariani, E., Baldanti, F., Palu, G., D'Agaro, P., Ansaldi, F., Affanni, P., Rossolini, G. M., Camilloni, B., Bagnarelli, P., Sanguinetti, Maurizio, Atripaldi, L., Chironna, M., Serra, C., Vitale, F., Germinario, C., Orsi, A., Manini, I., Montomoli, E., Napoli, C., Orsi, G. B., Casado, I., Castilla, J., Fernandino, L., Martinez-Baz, I., Ezpeleta, G., Navascues, A., Perez-Garcia, A., Aguinaga, A., Ezpeleta, C., Meijer, A., van den Brink, S., van der Hoek, W., Goderski, G., Wijsman, L., Bagheri, M., Dijkstra, F., de Lange, M., Marzec, T., Overduin, P., Teirlinck, A., Wentink, E., Donker, G., Marbus, S., van Gageldonk-Lafeber, R., Schneeberger, P., van Oosterheert, J. J., Schweitzer, V., Groeneveld, G., Nunes, B., Machado, A., Rodrigues, A. P., Gomez, V., Kislaya, I., Guiomar, R., Pechirra, P., Cristovao, P., Costa, I., Panarra, A., Corte-Real, R., Pocas, J., Peres, M. J., Comas, L. G., Marisquerena, M. E. I., Galan, J. C., Folgueira, M. D., Carril, F. G., Martinez, R. S., Cilla, G., Cenoz, M. G., Rubio, C. Q., Ochoa, E. M., Blasco, M., Duran, J. G., Vanrell, J. M., Reina, J., Castrillejo, D., Gherasim, A. M., Delgado, C., Oliva, J., Casas, I., Garcia, M., Latorre, M., Beamonte, A. M. M., Sapina, A. M., Amores, M. O., Aizpurua, A., Montes, M., Zakikhany, K., Brytting, M., Wiman, A., Carnahan, A., Warburton, F., Djennad, A., Ellis, J., Andrews, N., Marques, D., Cottrell, S., Reynolds, A., Gunson, R., Galiano, M., Lackenby, A., Robertson, C., O'Doherty, M., Sinnathamby, M., Yonova, I., Moore, C., Sartaj, M., de Lusignan, S., Zambon, M., Moren, A., Penttinen, P., and Sanguinetti M. (ORCID:0000-0002-9780-7059)

Abstract

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.

Published
2018

13. Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza

Author

Rondy, M., Launay, O., Castilla, J., Costanzo, S., Puig-Barbera, J., Gefenaite, G., Larrauri, A., Rizzo, C., Pitigoi, D., Syrjanen, R. K., Machado, A., Filipovic, S. K., Horvath, J. K., Paradowska-Stankiewicz, I., Marbus, S., Moren, A., Valenciano, M., Lenzi, N., Lesieur, Z., Loulergue, P., Galtier, F., Ray, M., Foulongne, V., Letois, F., Merle, C., Vanhems, P., Lina, B., Casado, I., Diaz-Gonzalez, J., Guevara, M., Martinez-Baz, I., Fernandino, L., Navascues, A., Ezpeleta, C., Chamorro, J., Barrado, L., Ortega, M. T., De Gaetano Donati, K., Cauda, R., Donato, C., Taccari, F., Campana, L., Santangelo, R., Perlasca, F., Fichera, G., Dara, M., Iacoviello, L., Olivieri, M., Alfonsi, V., Bella, A., Puzelli, S., Castrucci, M. R., Orsi, A., Ansaldi, F., Manini, I., Montomoli, E., Chironna, M., Germinario, C., Diez-Domingo, J., Sanudo, B., Carratala Munuera, C., Correcher Medina, P., Gil Guillen, V., Larrea Gonzalez, R., Limon Ramirez, R., Mico Esparza, J. L., Mollar Maseres, J., Otero Reigada, M. C., Tortajada Girbes, M., Schwarz Chavarri, G., Ambrozaitis, A., Jancoriene, L., Zablockiene, B., Zagminas, K., Aukse, M., Damuleviciene, G., Grimalauskaite, R., Kuliese, M., Lesauskaite, V., Velyvyte, D., Niesters, H., Stolk, R. P., Zagmines, K., Rahamat-Langendoen, J., Gherasim, A., Pozo, F., Altzibar, J., Arraras, J. G., Cilla, G., Marco, E., Vidal Garcia, M., Omenaca, M., Ivanciuc, A. E., Lupulescu, E., Lazar, M., Cherciu, C. M., Tecu, C., Mihai, M. E., Nitescu, M., Leca, D., Ceausu, E., Nohynek, H., Ikonen, N., Haveri, A., Gomez, V., Nunes, B., Rodrigues, A. P., Gomes, V., Corte-Real, R., Pocas, J., Peres, M. J., Visekruna Vucina, V., Kaic, B., Novosel, I. P., Petrovic, G., Ferenczi, A., Oroszi, B., Korczynska, M. R., Brydak, L. B., Cieslik-Tarkota, R., Rozwadowska, B., Skolimowska, G., Hulboj, D., Jakubik, A., Meijer, A., Van Gageldonk-Lafeber, A. B., Research Council of Lithuania, and European Union

Subjects
0301 basic medicine, Male, Veterinary medicine, Immunology and Microbiology (all), medicine.disease_cause, Polymerase Chain Reaction, Aged, Aged, 80 and over, Case-Control Studies, Clinical Laboratory Techniques, Europe, Female, Hospitalization, Humans, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus, Influenza Vaccines, Influenza, Human, Respiratory Tract Infections, Seasons, Sentinel Surveillance, Vaccination, Molecular Medicine, Veterinary (all), Public Health, Environmental and Occupational Health, Infectious Diseases, Seasonal influenza, IMOVE+, 0302 clinical medicine, 80 and over, Influenza A Virus, Influenza A virus, 030212 general & internal medicine, Respiratory tract infections, virus diseases, 3. Good health, H3N2 Subtype, Public Health, Human, medicine.medical_specialty, Influenza vaccine, 030106 microbiology, Virus, Hospital, 03 medical and health sciences, Repeated Vaccination, Internal medicine, medicine, H1N1 Subtype, Influenza Vaccine Effectiveness, General Veterinary, General Immunology and Microbiology, business.industry, Environmental and Occupational Health, Cuidados de Saúde, Case-control study, Influenza, Negative case, influenza vaccination, test negative case control, vaccine effectiveness, business
Abstract

In Europe, annual influenza vaccination is recommended to elderly. From 2011 to 2014 and in 2015-16, we conducted a multicentre test negative case control study in hospitals of 11 European countries to measure influenza vaccine effectiveness (IVE) against laboratory confirmed hospitalised influenza among people aged ≥65years. We pooled four seasons data to measure IVE by past exposures to influenza vaccination. We swabbed patients admitted for clinical conditions related to influenza with onset of severe acute respiratory infection ≤7days before admission. Cases were patients RT-PCR positive for influenza virus and controls those negative for any influenza virus. We documented seasonal vaccination status for the current season and the two previous seasons. We recruited 5295 patients over the four seasons, including 465A(H1N1)pdm09, 642A(H3N2), 278 B case-patients and 3910 controls. Among patients unvaccinated in both previous two seasons, current seasonal IVE (pooled across seasons) was 30% (95%CI: -35 to 64), 8% (95%CI: -94 to 56) and 33% (95%CI: -43 to 68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Among patients vaccinated in both previous seasons, current seasonal IVE (pooled across seasons) was -1% (95%CI: -80 to 43), 37% (95%CI: 7-57) and 43% (95%CI: 1-68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Our results suggest that, regardless of patients' recent vaccination history, current seasonal vaccine conferred some protection to vaccinated patients against hospitalisation with influenza A(H3N2) and B. Vaccination of patients already vaccinated in both the past two seasons did not seem to be effective against A(H1N1)pdm09. To better understand the effect of repeated vaccination, engaging in large cohort studies documenting exposures to vaccine and natural infection is needed. The Lithuanian I-MOVE+ study sites were supported by a grant from the Research Council of Lithuania (SEN-03/2015). The IMOVE+ project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446. GlaxoSmithKline, Sanofi Pasteur and Sanofi Pasteur MSD financially supported the InNHOVE network. They had no role in study design, data collection, pooled analysis, and publication. We are grateful to all patients, medical staff, study nurses and epidemiologists from the twelve study sites who actively participated in the study. info:eu-repo/semantics/publishedVersion

Published
2017

14. 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project

Author

Rondy, Marc, Larrauri, A., Casado, I., Alfonsi, V., Pitigoi, D., Launay, O., Syrjänen, R. K., Gefenaite, G., Machado, A., Vučina, V. V., Horváth, J. K., Paradowska-Stankiewicz, I., Marbus, S. D., Gherasim, A., Díaz-González, J. A., Rizzo, C., Ivanciuc, A. E., Galtier, F., Ikonen, N., Mickiene, A., Gomez, V., Kurečić Filipović, S., Ferenczi, A., Korcinska, M. R., Van Gageldonk-Lafeber, R., Valenciano, M., Altzibar, Jone M., Arraras, Ion Garcia, Cilla, Gustavo, Marco, Elisa, Vidal, Matxalen, Omenaca, Manuel, Castilla, J., Navascues, A., Ezpeleta, C., Barrado, L., Ortega, M. T., Bella, A., Castrucci, M. R., Puzelli, S., Chironna, M., Germinario, C., Ansaldi, F., Orsi, A., Manini, I., Montomoli, E., Lupulescu, E., Lazar, M., Cherciu, C. M., Tecu, C., Mihai, M. E., Nitescu, M., Leca, D., Ceausu, E., Lenzi, N., Lesieur, Z., Loulergue, P., Foulongne, V., Letois, F., Merle, C., Vanhems, P., Lina, B., Nohynek, H., Haveri, A., Kuliese, M., Velyvyte, D., Grimalauskaite, R., Damuleviciene, G., Lesauskaite, V., Jancoriene, L., Zablockiene, B., Ambrozaitis, A., Nunes, B., Rodrigues, A. P., Gomes, V., Corte-Real, R., Pocas, J., Peres, M. J., Kaić, B., Oroszi, B., Brydak, L. B., Cieślak, K., Kowalczyk, D., Szymański, K., Jakubik, A., Skolimowska, G., Hulboj, D., Meijer, A., Van Der Hoek, W., Schneeberger, P. M., Palmieri, Annapina, Giannitelli, Stefania, Ranghiasci, Alessia, Bacruban, Rodica, Azamfire, Delia, Dumitrescu, Aura, Ianosik, Elena, Duca, Elena, Bejan, Codrina, Teodor, Andra, Florescu, Simin-Aysel, Popescu, Corneliu, Tardei, Gratiela, Charpentier, Julien, Marin, Nathalie, Doumenc, Benoit, Le Jeunne, Claire, Krivine, Anne, Momcilovic, Sonia, Benet, Thomas, Amour, Selilah, Henaff, Laetitia, Jokinen, Jukka, Lyytikainen, Outi, Palmu, Arto, Siren, Paivi, Ruokokoski, Esa, Nunes, Baltazar, Rodrigues, Ana Paula, Guiomar, Raquel, Gomes, Victor, Quaresma, Filipa, Vale, Luis, Garcia, Teresa, Bernardo, Teresa, Dias, Liliana, Fonseca, Paula, Amorim, Helena, Rolo, Joao, Pacheco, Helena, Branquinho, Paula, Corte-Real, Rita, Pocas, Jose, Lopes, Paula, Peres, Maria Joao, Ribeiro, Rosa, Duarte, Paula, Pedroso, Ermelinda, Rodrigues, Sara, Silverio, Ana Rita, Pedreira, Diana Gomes, Fonseca, Marta Ferreira, Vince, Adriana, Topić, Antea, Papić, Neven, Mihalić, Jelena Budimir, Novosel, Iva Pem, Petrović, Goranka, Zajec, Martina, Draženović, Vladimir, Hercegh, Eva, Szalai, Balint, Antmann, Katalin, Nagy, Kamilla, Unión Europea, EpiConcept, Institute of Health Carlos III, CIBER de Epidemiología y Salud Pública (CIBERESP), Istituto Superiore de Sanita, University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), CIC Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi-Institut National de la Santé et de la Recherche Médicale (INSERM), F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Institut National de la Santé et de la Recherche Médicale (INSERM), National Institute for Health and Welfare [Helsinki], and National Institute for Public Health and the Environment [Bilthoven] (RIVM)

Subjects
Infecções Respiratórias, 0301 basic medicine, Male, Heart disease, Epidemiology, Efetividade da Vacina Antigripal, 0302 clinical medicine, Influenza A Virus, H1N1 Subtype, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Outcome Assessment, Health Care, 80 and over, Influenza A Virus, Medicine, 030212 general & internal medicine, Aged, 80 and over, [SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, Vaccination, virus diseases, 3. Good health, Europe, Hospitalization, Influenza Vaccines, case control, elderly, hospitalisation, influenza, severe acute respiratory infection, vaccine effectiveness, vaccine-preventable diseases, Vaccine-preventable diseases, Female, Public Health, Seasons, Research Article, Human, medicine.medical_specialty, Influenza vaccine, 030106 microbiology, Aged, Humans, Influenza B virus, Influenza, Human, Logistic Models, Outcome Assessment (Health Care), Sentinel Surveillance, Vaccine Potency, Public Health, Environmental and Occupational Health, Virology, Hospital, 03 medical and health sciences, Diabetes mellitus, Internal medicine, H1N1 Subtype, Vacina Antigripal, Intensive care medicine, business.industry, Environmental and Occupational Health, Cuidados de Saúde, Case-control study, medicine.disease, Influenza, Confidence interval, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, business
Abstract

Members of the I-MOVE+ project - Portugal: Baltazar Nunes, Ana Paula Rodrigues, Raquel Guiomar (Infectious Diseases Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal), Victor Gomes, Filipa Quaresma, Luis Vale, Teresa Garcia, Teresa Bernardo, Liliana Dias, Paula Fonseca, Helena Amorim, João Rolo, Helena Pacheco, Paula Branquinho, Rita Côrte-Real (Centro Hospitalar de Lisboa Central, Lisbon, Portugal),José Poças, Paula Lopes, Maria João Peres, Rosa Ribeiro, Paula Duarte, Ermelinda Pedroso, Sara Rodrigues, Ana Rita Silvério, Diana Gomes Pedreira, Marta Ferreira Fonseca, (Centro Hospitalar de Setúbal, Setúbal, Portugal). We conducted a multicentre test-negative case-control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases. The I-MOVE+ project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446. info:eu-repo/semantics/publishedVersion

Published
2017

17. Early estimates of seasonal influenza vaccine effectiveness in Europe among target groups for vaccination: results from the I-MOVE multicentre case-control study, 2011/12

Author

Kissling, E, Valenciano, M, I-MOVE Case-Control Studies Team, Jimenez-Jorge, Silvia, Mateo-Ontañon, Salvador de, Pozo Sanchez, Francisco, Casas Flecha, Inmaculada, Larrauri, Amparo, and European Centre for Disease Prevention and Control

Subjects
Adult, Aged, 80 and over, Male, Adolescent, Vaccination, Infant, Newborn, Infant, Middle Aged, Disease Outbreaks, Europe, Young Adult, Influenza A Virus, H1N1 Subtype, Treatment Outcome, Influenza Vaccines, Case-Control Studies, Child, Preschool, Influenza, Human, Confidence Intervals, Humans, Female, Seasons, Child, Sentinel Surveillance, Aged
Abstract

To provide an early estimate of 2011/12 influenza vaccine effectiveness (VE), we conducted a multicentre case-control study based on seven sentinel surveillance networks. We included influenza-like illness cases up to week 7/2012 from the vaccination target groups, swabbed less than eight days after symptom onset. Laboratory-confirmed influenza A(H3) cases were compared to negative controls. Adjusted VE was 43% (95% confidence interval: -0.4 to 67.7), suggesting low to moderate VE against influenza A(H3) in the early 2011/12 season. The I-MOVE network has been funded by the European Centre for Disease Prevention and Control (ECDC) since 2007. Sí

Published
2012

18. First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA Member States

Author

Valenciano M, Ciancio B, Moren A, and Influenza Vaccine Effectiveness Working Group

Subjects
medicine.medical_specialty, Epidemiology, Influenza vaccine, Population, Psychological intervention, MEDLINE, Disease Outbreaks, Interviews as Topic, Surveys and Questionnaires, Virology, Environmental health, Influenza, Human, medicine, Humans, media_common.cataloged_instance, European Union, European union, education, media_common, education.field_of_study, business.industry, Clinical study design, Public health, Public Health, Environmental and Occupational Health, Europe, Treatment Outcome, Influenza Vaccines, Population Surveillance, Seasons, business, Cohort study
Abstract

Estimating influenza vaccine effectiveness (IVE) early in the season helps measuring the consequences of a mismatch between the vaccine and the circulating strain and guiding alternative or complementary interventions. The European Centre for Disease Prevention and Control is funding a project to develop pilot studies to monitor IVE in the Member States (MS) of the European Union and European Economic Area (EU/EEA) during seasonal and pandemic influenza. To identify key methodological and practical issues in developing protocols for pilot studies, we conducted a survey among EU/EEA MS, a literature review on IVE methods, and consultations of experts. The survey and literature review highlighted the variety of the data sources used to estimate IVE and the difficulty to interpret data on IVE, which varies with age, risk group, outcome specificity and virus-vaccine mismatch. We also found that negative and positive confounding can bias IVE. The experts consultations lead to the following recommendations: to measure IVE in the same population in various seasons; to control for positive/negative confounding (including pre- and post-influenza season IVE estimates); and to include laboratory confirmation as outcome in various study designs. In the 2008-9 influenza season, two cohort studies using general practitioners' databases and six case control studies will be piloted in EU/EEA MS and will adhere to the above recommendations. The pilot studies will be the basis for the development of robust methods to monitor IVE in EU/EEA MS.

Published
2008

20. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case–control study, influenza season 2012/13

Author

Kissling, E, primary, Valenciano, M, additional, Buchholz, U, additional, Larrauri, A, additional, Cohen, J M, additional, Nunes, B, additional, Rogalska, J, additional, Pitigoi, D, additional, Paradowska-Stankiewicz, I, additional, Reuss, A, additional, Jiménez-Jorge, S, additional, Daviaud, I, additional, Guiomar, R, additional, O’Donnell, J, additional, Necula, G, additional, Głuchowska, M, additional, and Moren, A, additional

Published
2014
Full Text
View/download PDF

22. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case–control study

Author

Kissling, E, primary, Valenciano, M, additional, Larrauri, A, additional, Oroszi, B, additional, Cohen, J M, additional, Nunes, B, additional, Pitigoi, D, additional, Rizzo, C, additional, Rebolledo, J, additional, Paradowska-Stankiewicz, I, additional, Jiménez-Jorge, S, additional, Horváth, J K, additional, Daviaud, I, additional, Guiomar, R, additional, Necula, G, additional, Bella, A, additional, O’Donnell, J, additional, Głuchowska, M, additional, Ciancio, B C, additional, Nicoll, A, additional, and Moren, A, additional

Published
2013
Full Text
View/download PDF

23. I-MOVE multicentre case--control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine efectiveness with increasing time since vaccination?

Author

Kissling, E., Nunes, B., Robertson, C., Valenciano, M., Reuss, A., Larrauri, A., Cohen, J. M., Oroszi, B., Rizzo, C., Machado, A., Pitigoi, D., Domegan, L., Paradowska-Stankiewicz, I., Buchholz, U., Gherasim, A., Daviaud, I., Horváth, J. K., Bella, A., Lupulescu, E., and O'Donnell, J.

Published
2016
Full Text
View/download PDF

24. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.

Author

Valenciano, M., Kissling, E., Reuss, A., Rizzo, C., Gherasim, A., Horváth, J. K., Domegan, L., Pitigoi, D., Machado, A., Paradowska-Stankiewicz, I. A., Bella, A., Larrauri, A., Ferenczi, A., O'Donell, Joan, Lazar, M., Pechirra, P., Korczyñska, M. R., Pozo, F., and Moren, A.

Published
2016
Full Text
View/download PDF

29. “I-MOVE” towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9

Author

Kissling, E, primary, Valenciano, M, additional, Falcão, J M, additional, Larrauri, A, additional, Widgren, K, additional, Pitigoi, D, additional, Oroszi, B, additional, Nunes, B, additional, Savulescu, C, additional, Mazick, A, additional, Lupulescu, E, additional, Ciancio, B, additional, and Moren, A, additional

Published
2009
Full Text
View/download PDF

39. Informe presentado a la Sociedad Económica de Amigos del País de Santiago / [Salvador Parga, Manuel López y López, Isidro Casulleras, M. Valenciano, J. Seijas Moreno]

Author

Parga Torreiro, Salvador, López y López, Manuel, Casulleras Galiana, Isidoro, Valenciano, M., Seijas Moreno, J., Real Sociedad Económica de Amigos del País (Santiago de Compostela, Galicia), Parga Torreiro, Salvador, López y López, Manuel, Casulleras Galiana, Isidoro, Valenciano, M., Seijas Moreno, J., and Real Sociedad Económica de Amigos del País (Santiago de Compostela, Galicia)

Published
1888

40. Setting priorities for non-foodborne zoonoses

Author

Valenciano, M.

Abstract

En juillet 2000, l'Institut de veille sanitaire a re´uni un groupe d'experts pour de´finir les priorite´s et les moyens a` mettre en œuvre afin d'ame´liorer la connaissance, la pre´vention et le contro^le des zoonoses non alimentaires. Le groupe devait de´finir la liste des maladies a` conside´rer, hie´rarchiser les maladies en fonction de leur importance en sante´ publique, identifier les besoins pour chacune d'elles, juger de l'ade´quation des programmes et des syste`mes de surveillance en place a` ces objectifs. En cas d'inade´quation, des actions devaient e^tre propose´es pour atteindre ces objectifs et des priorite´s d'action de´termine´es. A` partir d'une premie`re liste de 37 maladies analyse´e en fonction de crite`res de´finis par le groupe, les maladies ont e´te´ classe´es comme prioritaires, importantes ou non prioritaires. Pour les maladies prioritaires et importantes, le processus de priorisation continue et les re´sultats seront disponibles en mai 2001.

Published
2001
Full Text
View/download PDF

41. Early estimates of seasonal influenza vaccine effectiveness in Europe among target groups for vaccination: Results from the I-MOVE multicentre case-control study, 2011/12

Author

Kissling, E., Valenciano, M., Ciancio, B. C., Kramarz, P., Nicoll, A., Moren, A., Savulescu, C., Cohen, J. M., Mosnier, A., Daviaud, I., Bui, T. T., Oroszi, B., Horváth, J. K., Caini, S., Rózsa, M., Rebolledo, J., O’malley, A., O’donnell, J., Domegan, L., Moran, J., Coughlan, S., Joyce, M., Collins, C., Rizzo, C., Bella, A., Rota, M. C., Giannitelli, S., Simona Puzelli, Donatelli, I., Declich, S., Stankiewicz, I. P., Gluchowska, M., Brydak, L., Kosek, A. W., Grzeganek, D., Nunes, B., Machado, A., Batista, I., Guiomar, R., Pechirra, P., Gonçalves, P., Conde, P., Falcão, I., Pitigoi, D., Ivanciuc, A. E., Lupulescu, E., Jiménez-Jorge, S., Mateo, S., Pozo, F., Ledesma, J., Casas, I., and Larrauri, A.

43. I-MOVE: a European network to measure the effectiveness of influenza vaccines

Author

Valenciano, M., Ciancio, Bc, I-Move, Study Team, Ciancio, B. C., Kramarz, P., Nicoll, A., Kissling, E., Moren, A., Savulescu, C., Seyler, T., Mazick, A., Widgren, K., Bui, T., Cohen, J. M., Daviaud, I., Mosnier, A., Oroszi, B., Caini, S., Csohan, A., Horvath, J. K., Rozsa, M., Barret, A. S., Domegan, L., O Donnell, J., Declich, S., Puzelli, S., Rizzo, C., Rota, M. C., Dieleman, J., Sturkenboom, M., Wijnans, L., Voordouw, B., Gluchowska, M., Paradowska-Stankiewicz, I., Stefanoff, P., Batista, I., Barreto, M., Conde, P., Falcao, J. M., Goncalves, P., Guiomar, R., Machado, A., Nunes, B., Pechirra, P., Helena Rebelo-de-Andrade, Santos, L., Falcao, I., Alexandrescu, V., Ivanciuc, A., Lupulescu, E., Pitigoi, D., Durnall, H., Fleming, D., Andrews, N., Hardelid, P., Kafatos, G., Pebody, R., Watson, J., Zambon, M., Kavanagh, K., Robertson, C., Mcmenamin, J., Reynolds, A., Larrauri, A., Jimenez-Jorge, S., Mateo, S., Pozo, F., Barricarte, A., Castilla, J., Garcia Cenoz, M., Martinez-Baz, I., and Guevara, M.

44. Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case–control study

Author

Kissling, E., Valenciano, M., Ciancio, B. C., Kramarz, P., Nicoll, A., Moren, A., Savulescu, C., Oroszi, B., Horváth, K. J., Csohán, Á, Saverio Caini, Rózsa, M., Barret, A. S., O’malley, A., O’donnell, J., Moran, J., Coughlan, S., Joyce, M., Collins, C., Rizzo, C., Bella, A., D’ancona, P., Giannitelli, S., Rota, M. C., Puzelli, S., Donatelli, I., Stankiewicz, I. P., Stefanoff, P., Gluchowska, M., Brydak, L., Romanowska, M., Nunes, B., Machado, A., Batista, I., Pechirra, P., Gonçalves, P., Conde, P., Falcão, I., Pitigoi, D., Baetel, A. E., Lupulescu, E., Jiménez-Jorge, S., Mateo, S., Pozo, F., Ledesma, J., Casas, I., and Larrauri, A.

50. A pilot sentinel surveillance system to monitor treatment and treatment outcomes of chronic hepatitis B and C infections in clinical centres in three European countries, 2019

Author

Anthony Nardone, Lina Nerlander, Erika Duffell, Marta Valenciano, Maria Buti, Cristina Marcos-Fosch, Tatjana Nemeth-Blažić, Odette Popovici, Adriana Vince, Petruta Violeta Filip, Tajana Filipec, Mirjana Lana Kosanović Ličina, Boris Luksic, Diana Nonković, Corina Silvia Pop, Fabiana Radu, Irina Teodorescu, Adriana Violeta Topan, Institut Català de la Salut, [Nardone A, Valenciano M] Epiconcept, Paris, France. [Nerlander L, Duffell E] European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden. [Buti M, Marcos-Fosch C] Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBEREHD del Instituto Carlos III, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
virosis::hepatitis viral humana::hepatitis C::hepatitis C crónica [ENFERMEDADES], Epidemiology, Public Health, Environmental and Occupational Health, Virus Diseases::Hepatitis, Viral, Human::Hepatitis C::Hepatitis C, Chronic [DISEASES], virosis::virosis::hepatitis viral humana::hepatitis B::hepatitis B crónica [ENFERMEDADES], Investigative Techniques::Epidemiologic Methods::Investigative Techniques::Epidemiologic Methods::Sentinel Surveillance [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS], Virology, acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS], Avaluació de resultats (Assistència sanitària), Virus Diseases::Virus Diseases::Hepatitis, Viral, Human::Hepatitis B::Hepatitis B, Chronic [DISEASES], Medicaments antivírics - Ús terapèutic, técnicas de investigación::métodos epidemiológicos::técnicas de investigación::métodos epidemiológicos::vigilancia centinela [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Hepatitis C - Tractament, Hepatitis B - Tractament
Abstract

Background The World Health Organization European Action Plan 2020 targets for the elimination of viral hepatitis are that > 75% of eligible individuals with chronic hepatitis B (HBV) or hepatitis C (HCV) are treated, of whom > 90% achieve viral suppression. Aim To report the results from a pilot sentinel surveillance to monitor chronic HBV and HCV treatment uptake and outcomes in 2019. Methods We undertook retrospective enhanced data collection on patients with a confirmed chronic HBV or HCV infection presenting at one of seven clinics in three countries (Croatia, Romania and Spain) for the first time between 1 January 2019 and 30 June 2019. Clinical records were reviewed from date of first attendance to 31 December 2019 and data on sociodemographics, clinical history, laboratory results, treatment and treatment outcomes were collected. Treatment eligibility, uptake and case outcome were assessed. Results Of 229 individuals with chronic HBV infection, treatment status was reported for 203 (89%). Of the 80 individuals reported as eligible for treatment, 51% (41/80) were treated of whom 89% (33/37) had achieved viral suppression. Of 240 individuals with chronic HCV infection, treatment status was reported for 231 (96%). Of 231 eligible individuals, 77% (179/231) were treated, the majority of whom had received direct acting antivirals (99%, 174/176) and had achieved sustained virological response (98%, 165/169). Conclusion Treatment targets for global elimination were missed for HBV but not for HCV. A wider European implementation of sentinel surveillance with a representative sample of sites could help monitor progress towards achieving hepatitis control targets.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results